Browsing Clinical Studies by author "Huang, Paul"
Now showing items 1-20 of 21
-
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
Peck, B; Bland, P; Mavrommati, I; Muirhead, G; Cottom, H; et al. (AMER ASSOC CANCER RESEARCH, 2021-02-15)Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies ... -
A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis.
Arthur, A; Orton, MR; Emsley, R; Vit, S; Kelly-Morland, C; et al. (ELSEVIER SCIENCE INC, 2023-11-01)BACKGROUND: Retroperitoneal sarcomas are tumours with a poor prognosis. Upfront characterisation of the tumour is difficult, and under-grading is common. Radiomics has the potential to non-invasively characterise the ... -
Characterisation of a Novel Cell Line (ICR-SS-1) Established from a Patient-Derived Xenograft of Synovial Sarcoma.
Kerrison, WGJ; Ning, J; Krasny, L; Arthur, A; Guljar, N; et al. (MDPI, 2022-08-04)Synovial sarcoma is a rare translocation-driven cancer with poor survival outcomes, particularly in the advanced setting. Previous synovial sarcoma preclinical studies have relied on a small panel of cell lines which suffer ... -
Clinical and Molecular Spectrum of Liposarcoma.
Lee, ATJ; Thway, K; Huang, PH; Jones, RL (LIPPINCOTT WILLIAMS & WILKINS, 2018-01-10)Liposarcomas are rare malignant tumors of adipocytic differentiation. The classification of liposarcomas into four principal subtypes reflects the distinct clinical behavior, treatment sensitivity, and underlying biology ... -
Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas.
Kerrison, WGJ; Lee, ATJ; Thway, K; Jones, RL; Huang, PH (MDPI, 2022-02-28)Immunotherapy in soft tissue sarcoma (STS) has experienced a surge of interest in the past decade, contributing to an expanding number of therapeutic options for this extremely heterogenous group of rare malignancies. ... -
Drug repositioning in sarcomas and other rare tumors.
Lee, ATJ; Huang, PH; Pollack, SM; Jones, RL (ELSEVIER SCIENCE BV, 2016-03-17) -
Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours.
Golčić, M; Jones, RL; Huang, P; Napolitano, A (MDPI, 2023-08-13)Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract. Surgical treatment is recommended for the majority of localised GIST, while systemic treatment is the cornerstone ... -
Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas.
Napolitano, A; Ostler, AE; Jones, RL; Huang, PH (MDPI, 2021-06-17)Sarcomas are a heterogeneous group of rare malignancies originating from mesenchymal tissues with limited therapeutic options. Recently, alterations in components of the fibroblast growth factor receptor (FGFR) signaling ... -
Immunotherapy of sarcomas with modified T cells.
Mahalingam, P; Julve, M; Huang, P; Furness, AJS; Pollack, SM; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-07-01)PURPOSE OF REVIEW: To summarize the development of modified T-cell therapies in sarcomas and discuss relevant published and ongoing clinical trials to date. RECENT FINDINGS: Numerous clinical trials are underway evaluating ... -
Novel therapeutic approaches in chondrosarcoma.
Polychronidou, G; Karavasilis, V; Pollack, SM; Huang, PH; Lee, A; et al. (FUTURE MEDICINE LTD, 2017-03-01)Chondrosarcoma is a malignant tumor of bones, characterized by the production of cartilage matrix. Due to lack of effective treatment for advanced disease, the clinical management of chondrosarcomas is exceptionally ... -
Olaratumab in soft tissue sarcoma - Current status and future perspectives.
Antoniou, G; Lee, ATJ; Huang, PH; Jones, RL (ELSEVIER SCI LTD, 2018-03-01)Recent randomised phase II trial data have indicated that the addition of olaratumab, a novel monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), to doxorubicin confers an unprecedented ... -
Pazopanib in advanced soft tissue sarcomas.
Lee, ATJ; Jones, RL; Huang, PH (NATURE PUBLISHING GROUP, 2019-05-17)Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular ... -
Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
Chamberlain, FE; Wilding, C; Jones, RL; Huang, P (TAYLOR & FRANCIS LTD, 2019-07-03)Introduction: Liposarcomas (LPS) are a heterogeneous group of adipocytic soft tissue sarcomas with limited treatment options in the advanced/metastatic setting. Pazopanib is a multi-target tyrosine kinase inhibitor (TKI) ... -
Pharmacotherapy for liposarcoma: current and emerging synthetic treatments.
Chamberlain, F; Benson, C; Thway, K; Huang, P; Jones, RL; et al. (TAYLOR & FRANCIS LTD, 2021-04-21)Liposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15-20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable ... -
Phase III Soft Tissue Sarcoma Trials: Success or Failure?
Lee, ATJ; Pollack, SM; Huang, P; Jones, RL (SPRINGER, 2017-03-01)Two recently reported phase III randomised control trials (RCTs) have resulted in the registration of two new systemic therapies for advanced soft tissue sarcoma. Both of these trials' designs were informed by phase II ... -
Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis.
Krasny, L; Wilding, CP; Perkins, E; Arthur, A; Guljar, N; et al. (MDPI, 2022-06-13)Intravenous leiomyomatosis (IVLM) is a rare benign smooth muscle tumour that is characterised by intravenous growth in the uterine and pelvic veins. Previous DNA copy number and transcriptomic studies have shown that IVLM ... -
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry.
Milighetti, M; Krasny, L; Lee, ATJ; Morani, G; Szecsei, C; et al. (ELSEVIER, 2021-06-15)Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic and epigenomic profiling of STS have been undertaken, proteomic analysis has thus far been limited. Here we utilise ... -
Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma.
Smrke, A; Thway, K; H Huang, P; Jones, RL; Hayes, AJ (FUTURE MEDICINE LTD, 2021-09-01)Solitary fibrous tumor (SFT) is a rare soft tissue sarcoma subtype which mainly affects adults in the fifth and sixth decades of life. Originally part of a spectrum of tumors called hemangiopericytomas, classification has ... -
The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma.
Lee, ATJ; Chew, W; Wilding, CP; Guljar, N; Smith, MJ; et al. (NATURE PORTFOLIO, 2019-10-10)The characterisation and clinical relevance of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma (LMS), a subtype of soft tissue sarcoma that exhibits histological heterogeneity, is not established. The use of tissue ... -
The evolving management of epithelioid sarcoma.
Alves, A; Constantinidou, A; Thway, K; Fisher, C; Huang, P; et al. (2021-07-18)